

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

NOTE: This special called meeting will be held virtually via Zoom webinar.

Thursday, May 19, 2022

1:00 P.M. to 4:00 P.M. (Eastern)

Access Information

Smartphone/Web	Dial-In
https://magellanhealth.zoom.us/j/93101597504 Webinar ID: 931 0159 7504 Password: 981071	+1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll) Webinar ID: 931 0159 7504 Passcode: 981071

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
 - a. Approval of March 2022 Meeting Minutes
- IV. New Business**
 - a. New Products to Market to be reviewed as single products:
 - i. Cibinqo™ (Cytokine and CAM Antagonists)
 - ii. Adbry™ (Immunomodulators, Atopic Dermatitis)
 - iii. Tavneos™ (Immunosuppressants)
 - iv. Leqvio® (Lipotropics: Other)
 - v. Vyvgart™ (Immunomodulators, miscellaneous)
 - vi. Besemri™ (Immunomodulators, miscellaneous)
 - vii. Tezspire™ (Immunomodulators, Asthma)
- I. New Therapeutic Classes**
 - a. Immunomodulators, Asthma
 - b. Uterine Disorder Treatments
- II. Therapeutic Classes with Recommended Changes**
 - a. Analgesics, Narcotics Short
 - b. Analgesics, Narcotics Long Acting
 - c. Antihyperuricemics
 - d. Antimigraine Agents, Other (Antimigraine Agents, CGRP Inhibitors)
 - e. Bone Resorption Suppression & Related Agents
 - f. Colony Stimulating Factors
 - g. Glucagon Agents
 - h. Glucocorticoids, Oral
 - i. Hypoglycemics, Incretin Mimetics/Enhancers (Diabetes: DPP4 Inhibitors)
 - j. Hypoglycemics, Insulins & Related

k. Phosphate Binders

V. Consent Agenda

a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none">• Androgenic Agents• Antimigraine Agents – Triptans (Antimigraine Agents - 5-HT1Receptor Agonists)• Erythropoiesis Stimulating Proteins• Growth Hormone• Hypoglycemics, AlphaglucoSIDase inhibitors (Diabetes: AlphaGlucoSIDase Inhibitors)• Hypoglycemics, Incretin Mimetics/Enhancers (Diabetes: GLP-1 Agonists)Hypoglycemics, Meglitinides (Diabetes: Meglitinides)• Hypoglycemics, Metformins (Diabetes: Metformins)• Hypoglycemics, SGLT2 Inhibitors (Diabetes: SGLT2 Inhibitors)• Hypoglycemics, Sulfonylureas (Diabetes: Sulfonylureas)	<ul style="list-style-type: none">• Hypoglycemics, Thiazolidinediones (TZD) (Diabetes: Thiazolidinediones)• Narcotics: Agonist/Antagonists• Narcotics: Fentanyl Buccal Products• Neuropathic Pain• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)• Opiate Dependence Treatments• Pancreatic Enzymes• Progestins for Cachexia• Skeletal Muscle Relaxants• Thrombopoiesis Stimulating Proteins (Thrombopoiesis Stimulating Agents)
--	---

V. Adjournment

a. Schedule of Upcoming Meetings

i. **July 21, 2022**

ii. **September 15, 2022**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to <https://kyportal.magellanmedicaid.com/provider/public/home.xhtml>.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.